Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Mesenchymal Tumor, Autoimmune Pancreatitis, Lymphoma, Solid Tumors
Interventions: EUS-FNB with ProCore needle, EUS-FNB with SharkCore needle, ProCore needle, SharkCore needle; Procedure · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Glucagon; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Epidural Placement
Interventions: BrightPoint; Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dermatitis, Atopic
Interventions: Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Pain, Epidural Analgesia
Interventions: 18G Tuohy epidural needle, CompuFlo® computerized syringe pump; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Yellow Fever
Interventions: Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA); Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2024
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
Interventions: elbasvir-grazoprevir (50 mg/100 mg); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Atrial Fibrillation
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Joseph Mathew, M.D.; Other
Eligibility: 50 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Harm Reduction, Opioid-use Disorder, Naloxone
Interventions: Nasal Spray Naloxone, Intramuscular Naloxone, Improvised Nasal Atomizer; Device
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Central Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib; Drug
Lead sponsor: Larysa Sanchez; Other
Eligibility: 70 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Huntsville, Alabama • Centennial, Colorado • Daytona Beach, Florida + 10 more

Conditions: Hip Osteoarthritis
Interventions: PRP, Hyaluronic Acid; Biological · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 72 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Wet Age-related Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 65
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: Faricimab PFS Configuration; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Mesa, Arizona • Phoenix, Arizona

Conditions: Nail Diseases
Interventions: Platelet-rich plasma, Platelet-poor plasma; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Local Anesthesia Injection Pain
Interventions: Local Anesthesia (lidocaine hydrochloride), Iontophoresis of Tetracaine and oxymetazoline; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Faricimab, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 85
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: Nasolabial Folds, Wrinkles
Interventions: TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • Beverly Hills, California • Santa Monica, California + 2 more

Conditions: Injections, Intradermal
Interventions: PATH ID Adapter; Device
Lead sponsor: PATH; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Renton, Washington

Conditions: Ricin Poisoning
Interventions: RVEc; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Leber Hereditary Optic Neuropathy (LHON)
Interventions: NR082 Injection, Injection needle; Drug · Device
Lead sponsor: Neurophth Therapeutics Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania

Search by objective public record fields.

Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

BrightPoint Reflectometer Device Study

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

"Loss of Resistance" Versus CompuFlo® for Epidural Placement

Human Immune Responses to Yellow Fever Vaccination

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

A Usability Assessment of Naloxone Administration by Untrained Community Members

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome

Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds

Performance and Safety Evaluation of an Intradermal Delivery Device

IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations